The role of aspirin in cancer prevention

  title={The role of aspirin in cancer prevention},
  author={Michael J. Thun and Eric J. Jacobs and Carlo Patrono},
  journal={Nature Reviews Clinical Oncology},
Clinical guidelines for prophylactic aspirin use currently only consider the cardiovascular benefits of aspirin, weighed against the potential harm from aspirin-induced bleeding. Daily aspirin use has been convincingly shown to reduce the risk of colorectal cancer and recurrence of adenomatous polyps, but in average-risk populations, these benefits alone do not outweigh harms from aspirin-induced bleeding. Recently published secondary analyses of cardiovascular trials provide the first… 
Aspirin and the Prevention of Colorectal Cancer
A substantial body of evidence from observational studies and randomized trials indicates that regular aspirin use reduces the risk of incident and fatal colorectal cancer and the identification of biomarkers of aspirin benefits and harms constitutes a key research priority.
Clinical evidence for the use of aspirin in the treatment of cancer
  • R. Langley
  • Medicine, Biology
  • 2013
Three new pieces of evidence: a series of meta-analyses focusing on cancer outcomes from randomised-controlled trials designed to assess the vascular benefits of daily aspirin; the first positive results from a randomised controlled trial designed to demonstrate that aspirin can prevent cancer in those with a hereditary predisposition; and observational data showing that aspirin use after a cancer diagnosis improves both cancer mortality and overall survival; have led to a re-evaluation of aspirin as a potential anti-cancer agent.
Aspirin and Cancer.
Role of Aspirin in Cancer Prevention
It is very likely that use of prophylactic aspirin in the general population aged 50–70+ years will result in net overall benefit, but outstanding issues are: whether standard dose can lead to greater net benefits than low dose, the optimum duration of use, and appropriate ages for use in average-risk individuals.
Aspirin and the Primary Prevention of Cardiovascular Diseases: An Approach Based on Individualized, Integrated Estimation of Risk
Clinical efforts at the individual level to promote the use of aspirin in global (or total) primary prevention could be already based on a balanced evaluation of the benefit/risk ratio.
Aspirin and Colorectal Cancer Prevention and Treatment: Is It for Everyone?
Emerging data suggest that tumour PIK3CA mutation status, expression of cyclo-oxygenase-2 and human leukocyte antigen class I, along with certain germline polymorphisms, might all help to identify individuals who stand to gain most from aspirin use.
Aspirin, cyclooxygenase inhibition and colorectal cancer.
Evidence supports the effectiveness of aspirin, as well as other non-steroidal anti-inflammatory drugs, for chemoprevention of several types of cancer, including CRC, including the prevention of adenoma recurrence and reduction of CRC incidence and mortality.
Antiplatelet Agents for Cancer Prevention: Current Evidences and Continuing Controversies
Current clinical evidence and continuing controversies on the potential chemoprotective properties of antiplatelet agents against cancer are summarized.


Aspirin in the Chemoprevention of Colorectal Neoplasia: An Overview
The case for consideration of long-term aspirin use in CRC prevention is strengthened, as there is a lack of consensus about the balance of risks and benefits associated with long- term aspirin use, particularly in low-risk populations.
Low-Dose Aspirin in the Primary Prevention of Cancer: The Women’s Health Study: A Randomized Controlled Trial
Results from this large-scale, long-term trial suggest that alternate day use of low-dose aspirin for an average 10 years of treatment does not lower risk of total, breast, colorectal, or other site-specific cancers.
Aspirin Use and Colorectal Cancer: Post-Trial Follow-up Data from the Physicians' Health Study
Whether 4 to 6 years of regular aspirin use reduced the incidence of colorectal cancer over a 12-year period is examined to shed light on the discrepancies between findings from observational studies and those from randomized trials.
Low-dose aspirin and incidence of colorectal tumors in a randomized trial.
Regular aspirin use, at a dose adequate for preventing myocardial infarction, was not associated with a substantial reduction in the incidence of colorectal cancer during 5 years of randomized treatment and follow-up.
Aspirin Use and Survival After Diagnosis of Colorectal Cancer
Findings show that use of aspirin after diagnosis of colorectal cancer is associated with improved survival from the disease, especially among patients with primary tumors that overexpress COX-2.
A randomized trial of aspirin to prevent colorectal adenomas.
Low-dose aspirin has a moderate chemopreventive effect on adenomas in the large bowel, using generalized linear models to compute risk ratios and 95 percent confidence intervals.